Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial

Kedhi E 1 , Verdoia M 2 , Suryapranata H 3 , Damen S 3 , Camaro C 3 , Benit E 4 Show all authors , Barbieri L 2 , Rasoul S 5 , Liew HB 6 , Polad J 7 , Ahmad WA 8 , Zambahari R 9 , Lalmand J 10 , van der Schaaf RJ 11 , Koh TH 12 , Timmermans P 4 , Dilling-Boer D 4 , Veenstra LF 5 , Van' T Hof AW 13 , Lee SW 14 , Roolvink V 13 , Ligtenberg E 15 , Postma S 16 , Kolkman EJ 16 , Brouwer MA 3 , Dudek D 17 , De Luca G 18

Affiliations 

  • 1 St-Jan Hospital, Brugge, Belgium
  • 2 AOU Maggiore della Carità, Eastern Piedmont University, Novara, Italy
  • 3 Radboud University Medical Center, Nijmegen, the Netherlands
  • 4 Jessa Ziekenhuis, Hasselt, Belgium
  • 5 Atrium Medical Center, Heerlen, the Netherlands
  • 6 Queen Elizabeth II, Sabah, Malaysia
  • 7 Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands
  • 8 University Malaya, Kuala Lumpur, Malaysia
  • 9 National Heart Institute, Kuala Lumpur, Malaysia
  • 10 Centre Hospitalier Universitaire,Charleroi, Belgium
  • 11 Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands
  • 12 National Heart Center, Singapore, Singapore
  • 13 Isala Hospital, Zwolle, the Netherlands
  • 14 Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
  • 15 OrbusNeich Medical BV, Hoevelaken, the Netherlands
  • 16 Diagram BV, Zwolle, the Netherlands
  • 17 Jagiellonian University Medical College, Krakow, Poland
  • 18 AOU Maggiore della Carità, Eastern Piedmont University, Novara, Italy. Electronic address: giuseppe.deluca@med.uniupo.it
Atherosclerosis, 2021 03;321:39-44.
PMID: 33639478 DOI: 10.1016/j.atherosclerosis.2021.02.006

Abstract

BACKGROUND AND AIMS: The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy.

METHODS: The REDUCE trial is a prospective, multicenter, investigator-initiated study that randomized ACS patients undergoing PCI with the COMBO drug eluting stent to either 3 or 12 months of DAPT. The study population was divided according to age (

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications